Clinical Trial Update: An Open-label Study of EZYPRO® in Atrial Fibrillation Detection on ESUS Patients [Phase 4]

View source ↗

Summary

Open-label Phase 4 trial evaluating EZYPRO® for detecting atrial fibrillation in patients with embolic stroke of undetermined source (ESUS).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation
• Embolic Stroke of Undetermined Source

Drugs mentioned

• EZYPRO®

Snippet

Sponsor: Sigknow Biomedical Co., Ltd. | Conditions: Atrial Fibrillation, Embolic Stroke of Undetermined Source | Phase 4 | Status: UNKNOWN